Aluminum-containing vaccine associated adverse events: role of route of administration and gender
Aluminum-containing vaccine associated adverse events: role of route of administration and gender
复制标题
DOI：
10.1016/s0264-410x(02)00172-x
复制
发表时间：
2002-05-31
期刊：
影响因子：
5.5
通讯作者：
Pittman, PR
中科院分区：
文献类型：
--
作者：
Pittman, PR
吸附炭疽疫苗（AVA）是一种含有氢氧化铝的疫苗，在18个月内皮下（SQ）接种6次。这是唯一的氢氧化铝许可SQ管理。为了优化疫苗接种方案和给药途径，进行了一项前瞻性初步研究，比较了使用较少剂量的肌内（IM）和SQ与许可的方案和途径。本报告提取了注射部位反应研究的数据。与IM相比，SQ接种疫苗时红斑和硬结更常见（分别为P < 0.0001，P = 0.002）。SQ结节仅见于SQ组（P < 0.0001）。AVA首次SQ给药后，女性中红斑、硬结和SQ结节比男性更常见（P <0.001）。当AVA前两次给药之间的间隔从2周增加到4周时，反应率降低。(C)2002年由Elsevier Science Ltd.出版
Anthrax vaccine, adsorbed (AVA) is a vaccine containing aluminum hydroxide that is administered as six subcutaneous (SQ) doses over 18 months. It is the only aluminum hydroxide licensed for SQ administration. To optimize the vaccination schedule and route of administration, a prospective pilot study comparing the use of fewer doses administered intramuscularly (IM) as well as SQ with the licensed schedule and route was performed. Data from that study on injection site reactions were extracted for this report. Erythema and induration occurred more commonly when the vaccine was administered SQ compared to IM (P < 0.0001, P = 0.002, respectively). SQ nodules were found only among the SQ group (P < 0.0001). Erythema, induration and SQ nodules were more common in women compared with men (P < 0,001) after the first SQ dose of AVA dose. Reaction rates decreased when the interval between the first two doses of AVA was increased from 2 to 4 weeks. (C) 2002 Published by Elsevier Science Ltd.